Cassava sciences announces completion of dosing in open-label study of simufilam for alzheimer's disease

Austin, texas, dec. 06, 2022 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for alzheimer's disease. this study was designed to evaluate long-term drug safety and to measure cognitive changes (adas-cog) over 12 months in approximately 200 patients with mild-to-moderate alzheimer's disease treated with open-label simufilam 100 mg twice daily. simufilam is cassava sciences' oral drug candidate for alzheimer's disease dementia.
SAVA Ratings Summary
SAVA Quant Ranking